Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition (Tables)

v3.22.4
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Contract with Customer, Asset and Liability
The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2022 and 2021 (in thousands):
2022 2021
Current pharma contract assets(1)
$ 1,898  $ 1,738 
Long-term pharma contract assets(2)
31  236 
Total pharma contract assets $ 1,929  $ 1,974 
Current pharma capitalized commissions(1)
$ 800  $ 109 
Long-term pharma capitalized commissions(2)
715  882 
Total pharma capitalized commissions $ 1,515  $ 991 
Current pharma contract liabilities $ 7,557  $ 5,192 
Long-term pharma contract liabilities(3)
19  917 
Total pharma contract liabilities $ 7,576  $ 6,109 
(1) Recorded within other current assets on the Consolidated Balance Sheets.
(2) Recorded within other assets on the Consolidated Balance Sheets.
(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.
Schedule of Disaggregation of Revenue
The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2022, 2021 and 2020 (in thousands):
2022 2021 2020
Clinical Services:
    Client direct billing $ 279,732  $ 252,617  $ 240,535 
    Commercial insurance 73,280  78,773  76,550 
    Medicare and other government 65,585  72,010  64,776 
    Self-pay 157  772  476 
Total Clinical Services 418,754  404,172  382,337 
Pharma Services 90,974  80,157  62,111 
Total net revenue $ 509,728  $ 484,329  $ 444,448